Derivatives contain dimethylaminopyridine as SIRT2 inhibitors: A mini review

Mostafa M. Badran1,2,3, Samar H Abbas1,4, Mikako Fujita4, Mohamed Abdel-Aziz2

1 Department of Medicinal Chemistry, Faculty of Pharmacy, South Valley University, Qena, 83523, Egypt.
2 Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519-Minia, Egypt.
3 Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan

Received: June 21, 2023; revised: July 14, 2023; accepted: July 19, 2023

Abstract

The development of new compounds inhibiting SIRT2, a protein that regulates various biological processes, has attracted significant attention in recent years. This study reported dimethylaminopyridine (DMAP) synthesis and evaluation as a new scaffold for SIRT2 inhibition. DMAP derivatives were designed and synthesized using a combination of computational modeling and synthetic chemistry approaches. A high-throughput screening assay was used to evaluate the ability of compounds to inhibit SIRT2. The most potent compounds were identified and further characterized using cellular and enzymatic assays. This review suggests that DMAP could be a promising scaffold for developing novel SIRT2 inhibitors with potential anticancer activity.

Keywords:
Dimethylaminopyridine; HDACs, SIRT2 inhibitors

1. Introduction

Histone deacetylases HDACs are a class of enzymes that remove acetyl groups from histone proteins. Histones are responsible for DNA package into a compact structure called chromatin, which regulates gene expression. Acetylation of histones is proceeded by histone acetyltransferases (HATs) which are generally associated with gene activation. Conversely, deacetylation is run by HDACs associated with gene repression.[1-4]

There are four classes of HDACs:
• Class I HDACs - HDAC1, HDAC2, HDAC3, and HDAC8. They are mainly localized in the nucleus and are critical in gene expression regulation.
• Class II HDACs - HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10. They have nuclear and cytoplasmic localization and are involved in diverse biological processes.
• Class III HDACs are also known as sirtuins (SIRT1- SIRT7) and require NAD⁺ as a cofactor to deacetylate lysine residues. They are implicated in energy metabolism, stress response, and aging.
• Class IV HDACs comprise only one member, HDAC11, and have features of both Class I and Class II enzymes.[5] Sirtuins utilize NAD⁺ as a co-factor for deacetylation process (Figure 1).[6] Sirtuins constitute seven isoforms Sirt 1-7. They share the catalytic domain of 260 amino acids and were differentiated by the length of N and C amino acids.[7]

Figure 1. The proposed catalytic mechanism of deacetylation of N- terminal lysine acids by Sirtuins.[6]

Sirtuins mediate a vast array of physiological processes such as gene transcription, inflammation, cell cycle progression, apoptosis, autophagy, metabolism, aging, and mitochondrial function.[8,9] SIRT1 is considered the most well-studied sirtuin member and plays an important role in aging, metabolism, and cancer.[10] SIRT2 participates in DNA repair and cell survival. SIRT3 mediates mitochondrial function and aging.[11] SIRT4 is involved in inflammation and insulin resistance.[12] SIRT5 is involved in ammonia disposal and regulation.[13] SIRT6 is involved in the regulation of ribosomes and aging.[14] SIRT7 helps in DNA repair by promoting ribosomal RNA and aging.[15]
SIRT2 isoform was reported to deacetylate histone H4 substrate and non-histone substrates as p46, FOXO1, and α-tubulin. SIRT2 has a crucial role in cancer due to its cellular activity. Its activity varied between suppressing tumors as glioma cells or promotion as in neuroblastoma or pancreas cancer cells. In addition, it showed oncogenic activity as it stabilizes the Myc-oncoprotein. Additionally, SIRT2 protein promotes mTOR activation and it increases cell growth of colorectal carcinoma cells. SIRT2 protein was overexpressed in renal cell carcinoma stem-like cells and regulated cancer metastasis. Other findings demonstrated a role of SIRT2 and HDAC6 in cell migration and invasion to bladder cancer cells via targeting actin cytoskeleton. The crystal structure of SIRT2 comprises two domains. The small domain conserved zinc ion. The large domain constitutes Rossmann fold for NAD+ binding. Between the two domains, the active site was located. The active site contains many hydrophobic pockets including A, B, and C, selectivity, and acetyl lysine (Figure 2).

Figure 2. Crystal structure of human SIRT2 enzymes (PDB ID: 4mg) containing the active site

2. SIRT2 inhibitors

The natural pan inhibitor for Sirtuin isoformes, nicotinamide (NAM) I, showed no selectivity towards SIRT1 and 2.[25] Furthermore, Sirtinol II was the 1st synthesized SIRT inhibitor that possessed moderate selectivity towards SIRT2. It had IC50 values of 68 μM and 38 μM against SIRT1 and SIRT2, respectively. The meta and para analogues of sirtinol possessed 2-10 folds more potent than α-isomer as SIRT1 and 2 inhibitors.[26] The drug showed potent cytotoxicity against MCF-7 breast cancer and H1299 lung cancer cell lines.[27] Further investigations were being conducted on the utilization of the hydroxy naphthyl group as cambinol III and compound IV.[28-30] Cambinol III showed potent inhibitory activity in the mice Burkitt lymphoma xenograft model. It induced apoptosis via hyperacetylation of p53 and BCL6 oncoprotein.[29] But the two compounds III and IV showed no selectivity towards SIRT1 and 2. On the other side, the highly potent SIRT2 inhibitors, compounds Va and Vb, were innovated by Suzuki et al. based on the modification of 2-anilinobenzamide, and they possessed submicromolar inhibitory activity. Compounds Va, b showed high selectivity toward SIRT2 with IC50 values equal to 1 μM and 0.57 μM, respectively, against SIRT2. In contrast, their IC50 values versus SIRT1 were more than 300 μM. Additionally, Compound Va induced the hyperacetylation of tubulin in human colon cancer HCT116 cells.[31,32]

The naphthyl group had a pivotal role in the binding of Sirtuin inhibitors, and it forms hydrophobic interactions with the hydrophobic binding site. Another lead compound harnessing the naphthyl group was SirReal2 VI.[33] The compound VI showed the most potent inhibitory activity among a series of six derivatives with an IC50 value of 0.4 μM against SIRT2.

Figure 3. The 2D of compound VI within the active site of SIRT2 enzyme (PDB code 4RMG)

Substituted aminopyridine as cytotoxic agents

Compound VII bearing a dimethylaminopyridyl histidine fragment, was designed as a Bleomycin-like ligand[32] to induce apoptosis in human pancreatic carcinoma cells. The results revealed that compound VII was proficient in inducing apoptosis in these cancer cells. The mechanism of action was observed as the activation of reactive oxygen species (ROS) and the down-regulation of anti-apoptotic proteins like Bcl-2. Additional experiments confirmed that compound VII-induced apoptosis
was independent of the p53 pathway and had no cytotoxic effect on non-cancerous cells.

Further development of the previous compound was performed by T. Ali and coworkers. The authors synthesized a series of compounds by modifying substituents of the imidazole rings. The modifications included the addition of mono- and dibenzyl, trityl, or methyl groups. They evaluated the cytotoxicity of these compounds against three human cancer cell lines: breast, colon, and lung. The results showed that the imidazole-substituted derivatives exhibited higher cytotoxicity than the non-substituted ones. The two most active compounds were VII and VIII. Also, the researchers investigated the mechanism of action of the imidazole-substituted compounds. They found that these compounds induced cell death by apoptosis and inhibited the migration and invasion of cancer cells. Additionally, the compounds were found to chelate metal ions, which may contribute to their anticancer activity.

Substituted aminopyridine as SIRT2 inhibitors

Compounds VII, VIII, and fifteen compounds were screened as SIRT2 inhibitors from the chemical library of T. Ali et al. The compound's design is based on linking the tritylhistidine group to the dimethylaminopyridine scaffold. The examined compounds VII and VIII showed potent activity with IC₅₀ values of 5.5 μM and 8.8 μM, respectively. Firstly, compound X was prepared by simplification of the original previously mentioned two compounds. Compound X was synthesized via reductive amination of N,N-dimethyl-4-aminopyridin-2-carbaldehyde with trityl histidine intermediate compound IX. The inhibition activity of compounds IX and X was screened, and the results indicated that the trityl histidine intermediate compound IX showed negligible low SIRT2 enzyme activity, recording an IC₅₀ value of 43 μM. While compound X exhibited higher potency than the previous lead compounds VII and VIII against SIRT2, showing an IC₅₀ value equal to 1.7 μM. Therefore, they synthesized thirteen derivatives XI-XXIII to enhance the activity of X.

Worthily, compounds bearing dimethyl and diethylaminomethylpyridine motif exhibited higher activity and had IC₅₀ of 1.3 μM and 1.7 μM, respectively. While compound XXII had lower activity (IC₅₀: 20 μM) and compound XXIII with bis benzyl groups had negligible inhibitory activity (IC₅₀ >100 μM). In addition, the cytotoxicity activities of some selected compounds were evaluated against MCF7, K562, and MT-2 cell lines (Table 1). All the examined compounds have more potent cytotoxicity against SIRT-2 sensitive MCF-7 than Sireal2 VI. On the other side, the higher cytotoxicity of the selected compounds against K562 and MT-2 versus the lower potency of Sireal2 might be related to the activity of these compounds through DNA cleavage as VII and VIII. The docking study of XI matches with the in vitro results. The docking study revealed that the dimethylaminopyridine moiety interacted with Ile 169 of the selectivity pocket in a pattern like that of the Sireal2 VI dimethyl pyrimidine group. Also, the trityl group occupied the acetyl-lysine pocket (Figure 4). Table 1. Cytotoxicity of selected trityl histidine derivatives against MCF-7, K562, and MT-2 cell lines (IC₅₀ (μM)).

<table>
<thead>
<tr>
<th>Compound</th>
<th>MCF-7 IC₅₀ (μM)</th>
<th>K562 IC₅₀ (μM)</th>
<th>MT-2 IC₅₀ (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VII</td>
<td>1.7 ± 0.51</td>
<td>7.9 ± 1.12</td>
<td>8.86 ± 1.38</td>
</tr>
<tr>
<td>VIII</td>
<td>2.29 ± 0.43</td>
<td>6.51 ± 0.89</td>
<td>8.61 ± 1.0</td>
</tr>
<tr>
<td>X</td>
<td>0.77 ± 0.08</td>
<td>7.53 ± 0.55</td>
<td>3.53 ± 0.44</td>
</tr>
<tr>
<td>XI</td>
<td>0.71 ± 0.06</td>
<td>6.27 ± 0.91</td>
<td>4.36 ± 0.62</td>
</tr>
<tr>
<td>XIII</td>
<td>11.9 ± 1.2</td>
<td>10.4 ± 1.1</td>
<td>6.81 ± 0.42</td>
</tr>
<tr>
<td>XV</td>
<td>8.96 ± 1.03</td>
<td>6.36 ± 0.73</td>
<td>1.75 ± 0.11</td>
</tr>
<tr>
<td>XVIII</td>
<td>9.87 ± 1.27</td>
<td>5.35 ± 0.59</td>
<td>1.37 ± 0.08</td>
</tr>
<tr>
<td>Sireal2 VI</td>
<td>13.7 ± 2.2</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
</tbody>
</table>

Figure 4. 2D interaction of X with the active site of SIRT2 enzyme (PDB code 4RMG)
SirReal2

VI (IC₅₀ = 0.21 ± 0.02)

 VII (IC₅₀ = 8.8 ± 1.7 µM)

 VIII (IC₅₀ = 5.5 ± 0.5 µM)

 IX (IC₅₀ = 43.0 ± 0.8 µM)

 X (IC₅₀ = 1.7 ± 0.0 µM)

 XI (IC₅₀ = 1.3 ± 0.2 µM)

 XII (IC₅₀ = 5.6 ± 0.1 µM)

 XIII (IC₅₀ = 11.8 ± 0.3 µM)

 XIV (IC₅₀ = 16.4 ± 1.1 µM)

 XV (IC₅₀ = 21.8 ± 1.0 µM)

 XVI (IC₅₀ = 10.2 ± 0.3 µM)

 XVII (IC₅₀ = 6.7 ± 1.5 µM)

 XVIII (IC₅₀ = 5.9 ± 0.4 µM)

 XIX (IC₅₀ = 7.5 ± 1.6 µM)

 XX (IC₅₀ = 2.5 ± 0.3 µM)

 XXI (IC₅₀ = 3.3 ± 0.8 µM)

 XXII (IC₅₀ = 20.4 ± 3.1 µM)

 XXIII (IC₅₀ = >100 µM)
Radwan and his co-workers developed new series of cysteine methyl esters containing SIRT2 inhibitors. The structure development was achieved through structural modification of the previous potent compound XI by conserving the essential triaryl group and replacing methyl histidine linker with methyl cysteine. Also, the design includes the incorporation of different terminal aryl groups. SIRT2 screening of the synthesized compounds revealed the high potency of compounds XXVIII, XXXII, and XXXV (Table 2). They possessed IC\textsubscript{50} values of 17.2 μM, 10.8 μM, and 9.5 μM, respectively. These results confirmed the importance of diethyl and dimethyl aminopyridine for the activity. Moreover, they proposed the loss of the activity of XXXIV may be related to the free rotation of XXVIII compared with XXXIV. Additionally, the cytotoxicity of these three compounds, XXVIII, XXXII, and XXXV, was tested versus five different cancer cell lines compared to the cytotoxicity of compound XI and Sireal2 VI. Compounds XXVIII and XXXIII had high and close cytotoxicity values, especially against HL-60 leukemia cell lines (Table 3).

Notably, the hydrazide derivative showed less relative cytotoxicity owing to its higher polarity and lower cellular penetration ability. The higher cytotoxicity of the active compounds than Sireal2 was explained by DNA cleavage screening at one micromole concentration. Compounds XXVIII, XXXIII, and XXXV showed strong DNA cleavage, like compound XI. So, they acted by dual SIRT2 inhibition/DNA cleavage activities. The docking study of the most active compound XXVIII showed a similar binding mode to XXIV except for adaption in the selectivity pocket. The long histidine moiety of XI seemed to be more adaptable in the selectivity pocket than the short methyl cysteine of XXVIII. In addition, the dimethylamino group linked to the pyridine ring is not adapted correctly with XXVIII than XI. Furthermore, the replacement of the dimethylamino group with long diethyl caused interference interaction with Leu 138; this indicated the higher potency of XXVIII over XXXIII. The inhibition activity of XXXV was attributed to the hydrogen bonding of Asn168 forms with the hydrazide group.[35]
Table 2. The in vitro SIRT2 inhibitory activity of compounds XXIV-XXXV versus XI

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC₅₀ against SIRT2 (µM)</th>
<th>Compound</th>
<th>IC₅₀ against SIRT2 (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>XXIV</td>
<td>&gt; 100</td>
<td>XXXI</td>
<td>&gt; 100</td>
</tr>
<tr>
<td>XXV</td>
<td>&gt; 100</td>
<td>XXXII</td>
<td>&gt; 100</td>
</tr>
<tr>
<td>XXVI</td>
<td>&gt; 100</td>
<td>XXXIII</td>
<td>17.2 ± 1.2</td>
</tr>
<tr>
<td>XXVII</td>
<td>&gt; 100</td>
<td>XXXIV</td>
<td>&gt; 100</td>
</tr>
<tr>
<td>XXVIII</td>
<td>10.8 ± 1.9</td>
<td>XXXV</td>
<td>9.5 ± 1.2</td>
</tr>
<tr>
<td>XXIX</td>
<td>&gt; 100</td>
<td>XI</td>
<td>1.3 ± 0.2</td>
</tr>
<tr>
<td>XXX</td>
<td>&gt; 100</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3. IC₅₀ values of selected compounds against multiple cancer cell lines.

<table>
<thead>
<tr>
<th></th>
<th>MCF-7</th>
<th>HeLa</th>
<th>K562</th>
<th>MT-2</th>
<th>HL-60</th>
</tr>
</thead>
<tbody>
<tr>
<td>SirReal2 VI</td>
<td>17.08±2.15</td>
<td>10.37±0.94</td>
<td>13.65±0.44</td>
<td>17.86±1.52</td>
<td>90.6±8.77</td>
</tr>
<tr>
<td>XXVIII</td>
<td>3.16±0.26</td>
<td>1.56±0.17</td>
<td>2.17±0.25</td>
<td>3.15±0.13</td>
<td>0.45±0.05</td>
</tr>
<tr>
<td>XXXIII</td>
<td>3.32±0.41</td>
<td>2.72±0.19</td>
<td>2.53±0.31</td>
<td>2.55±0.28</td>
<td>1.19±0.09</td>
</tr>
<tr>
<td>XXXV</td>
<td>10.03±1.12</td>
<td>7.95±0.81</td>
<td>14.99±1.17</td>
<td>16.82±1.04</td>
<td>12.78±0.95</td>
</tr>
<tr>
<td>XI</td>
<td>0.71±0.08</td>
<td>0.37±0.04</td>
<td>0.30±0.02</td>
<td>0.17±0.02</td>
<td>0.28±0.04</td>
</tr>
</tbody>
</table>

Another approach was carried out by the previous team utilizing a cysteamine linker instead of a methyl cysteine ester linker. The synthesized compounds were tested as SIRT2 inhibitors using an electrophoretic mobility test. Firstly, the parent compound XXXVI showed no activity (Table 4).

![XXXVI](image)

Compound XXXVII devoid of the ester group displayed higher activity than XXVIII, with an IC₅₀ value of 7.5 µM. The activity was dramatically decreased by removing the dimethylamino group (IXL had an IC₅₀ value of 39.3 µM). Moreover, removing the dimethyl aminopyridine moiety or its replacement with other aromatic groups abolishes the activity (e.g., XXXVIII, IXL, and XLI). The results reflected the pivotal role of the basic pyridine ring (which is enhanced by a 4-dimethyl amino group) in the activity. XLI-bearig diethylaminopyridine has comparable inhibition activity to XXXVII (IC₅₀ = 7.5 µM). Interestingly, the docking study of XXXVII, XXVIII, and Sirreal2 with SIRT2 revealed a high degree of alignment of XXXVII with Sirreal2 compared to XXVIII. Moreover, removing carboxymethyl ester from XXVIII allowed the protonation of pyrimidine NH of XXXVII to form an H-bonding with Ala135 in the selectivity pocket.[36]
Conclusion

In this review, dimethylamino pyridine (DMAP) development as a new scaffold for SIRT2 inhibition has shown promising results. The combination of molecular modeling and synthetic chemistry approaches allowed the design and synthesis of several DMAP derivatives, which were then evaluated for their ability to inhibit SIRT2. The most potent compound, XI, was further assessed as a cytotoxic drug providing essential insights into the mechanism of action of DMAP as a new building block for SIRT2 inhibitors. These findings suggest that DMAP could be a valuable tool for developing novel SIRT2 inhibitors with potential therapeutic applications in various diseases. Further studies are warranted to explore the full potential of DMAP and its derivatives in this context.

References
